Kbi-110 !link! -
Report: KBI‑110 – Technical, Commercial, and Strategic Overview
(Prepared: 11 April 2026)
The Breakthrough of KBI-110: Unlocking New Avenues in Immune-Oncology KBI-110
Biomarker‑Driven Development – A BRD9‑activity signature (derived from ATAC‑seq and RNA‑seq) is being validated as a predictive biomarker to enrich for responders in both oncology and fibrotic diseases. Chemical compound
Final Takeaway
KBI-110 isn't a cure yet, and it isn't on the market. But it is a perfect lens through which to view the evolution of cancer treatment. We have moved from "kill everything" (chemotherapy) to "release the brakes" (checkpoint inhibitors) to "manually steer the attack" (bispecifics). Report: KBI‑110 – Technical
Resistance Mechanisms
Tumor cells could up‑regulate compensatory bromodomain proteins (e.g., BRD7) or acquire BRD9 point mutations in the allosteric pocket. Early resistance monitoring (ctDNA sequencing) is planned in the AML trial.
- Chemical compound?
- Pharmaceutical or medical term?
- Technical or scientific concept?
- Product or brand name?